Apd-668

HCID 11705608CAS 832714-46-2

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

Standard-SMILES: CC(C)OC(=O)N1CCC(Oc2ncnc3c2cnn3-c2ccc(S(C)(=O)=O)cc2F)CC1
InChIKey: XTRUQJBVQBUKSQ-UHFFFAOYSA-N
Summenformel: C21H24FN5O5S
Durchschnittliche Molmasse: 477,5 g/mol
Monoisotopische Masse: 477,14821809

Überblick

APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also avoid hypoglycemia.

Namen und Bezeichner

Bevorzugter Name: Apd-668
IUPAC: propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[5,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate
Englischer Name: APD668
Summenformel: C21H24FN5O5S
Molmasse: 477.51

Namen und Synonyme

APD668832714-46-2APD-668JNJ-28630368JC77BCH2APRefChem:113299Isopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylateMFCD12032117isopropyl 4-(1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)piperidine-1-carboxylateCHEMBL1775179propan-2-yl 4-[1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylateisopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylate .

Weitere Namen anzeigen

CS-1179APD 668, >=98%APD 668APD668, 10 mM in DMSOisopropyl 4-(1-(2-fluorine-4-(carbosulfonyl)phenyl)-1H-pyrazolo[3,4-D]pyrimidine-4-oxy)piperidine-1-carboxylate4-[[1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester1-Piperidinecarboxylic acid,4-[[1-[2-fluoro-4-(methylsulfonyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy]-, 1-methylethyl esterInhibitor,CYPs,APD668,diabetes,Cytochrome P450,APD-668,GPR119,Potassium Channel,coupled,G-protein,steatohepatitis,CYP2C9,G Protein-Coupled Receptor 119,inhibit,KcsAisopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)oxy)piperidine-1-carboxylate APD668

ISOPROPYL 4-{[1-(2-FLUORO-4-METHANESULFONYLPHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]OXY}PIPERIDINE-1-CARBOXYLATEpropan-2-yl 4-{[1-(2-fluoro-4-methanesulfonylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]oxy}piperidine-1-carboxylate1-Methylethyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)-1-piperidinecarboxylate1-Piperidinecarboxylic acid, 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)-, 1-methylethyl ester4-((1-(2-Fluoro-4-methylsulfonylphenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)piperidine-1-carboxylic acid isopropyl esterIsopropyl 4-((1-(2-fluoro-4-(methylsulfonyl)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-yl)oxy)-1-piperidinecarboxylatePropan-2-yl 4-(1-(2-fluoro-4-methylsulfonylphenyl)pyrazolo(4,5-E)pyrimidin-4-yl)oxypiperidine-1-carboxylatepropan-2-yl 4-[1-(2-fluoranyl-4-methylsulfonyl-phenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate

Datenbank-Bezeichner

CAS: 832714-46-2
PubChem CID: 11705608
DTXSID: DTXSID701025686
ChEMBL: CHEMBL1775179
UNII: JC77BCH2AP
Nikkaji: J3.130.251J

Eigenschaften

Berechnete Struktureigenschaften

XLogP: 2,7
Polarare Oberfläche (TPSA): 125 Å²
H-Brücken-Donoren: 0
H-Brücken-Akzeptoren: 9
Frei drehbare Bindungen: 6
Schwere Atome: 33
Formalladung: 0
Komplexität: 788

Experimentelle und physikochemische Eigenschaften

LogP3.0

Physikochemische Eigenschaften

Siedepunkt: 611.6 · 611.6±55.0 °C(Predicted)
Dichte: 1.47 · 1.47±0.1 g/cm3(Predicted)
storage temp.: -20 °C · Store at -20°C
Löslichkeit: 2 O; · insoluble in H2O; ≥17.4 mg/mL in DMSO; ≥2.61 mg/mL in EtOH with gentle warming and ultrasonic
Aggregatzustand: solid
pka: 2.13 · 2.13±0.30(Predicted)
Farbe: White to off-white

Sicherheit und Regulatorisches

Sicherheitsdaten

Alarmwort: Warnung
Gefahrenhinweise: Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H315

Chemie und Industrie

Pharmakologische Informationen

Mechanism of Action · 1 Eintrag

The GDIR mechanism is glucose dependent: in preclinical studies, GDIR agonists only lowered blood glucose when it rose above normal levels, such as after a meal. Therefore, unlike the glucose-insensitive sulfonylureas, Arena's GDIR agonists are not expected to lower normal fasting blood glucose levels or cause hypoglycemia. In addition, GDIR stimulation has been found to increase the levels and activity of intracellular factors thought to be involved in the preservation of beta cells.